Biodexa Pharmaceuticals Plc has announced a major milestone in its clinical development program. The company has successfully enrolled 100 patients in its registrational Phase 3 trial for eRapa, a treatment targeting Familial Adenomatous Polyposis (FAP). This achievement is crucial as it marks a significant step toward potentially bringing a new therapeutic option to patients suffering from this hereditary condition.

The Phase 3 trial, branded as Serenta, is currently recruiting participants at 29 clinical sites across the United States and five European countries, with plans to initiate additional sites in Canada shortly. The trial protocol includes a planned futility analysis after 25 Progression Free Survival (PFS) events, with a database lock anticipated after 75 PFS events.

Stephen Stamp, CEO of Biodexa, commented on this achievement, stating, “Enrolment of the 100th patient represents an important milestone for Serenta and reflects the continued strong recruitment performance across our participating sites. Based on the current rate of PFS event accrual, the pre-specified futility analysis could take place early next year with database lock potentially occurring around the end of next year, both significantly sooner than originally anticipated.”

Background

Biodexa Pharmaceuticals Plc, traded on Nasdaq under the ticker BDRX, is a clinical-stage biopharmaceutical company focused on developing innovative products for treating gastrointestinal cancers. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Biodexa has been actively pursuing the development of its lead product, eRapa, along with other therapies aimed at addressing unmet medical needs in oncology.

What the Filing Says

The recent filing, dated October 14, 2026, highlights the enrollment of 100 patients in the Phase 3 trial for eRapa, a significant milestone for the company. The filing notes, “The trial, branded ‘Serenta,’ is recruiting at 29 clinical sites across the US and five countries in Europe.”

Impact

This development may significantly affect stakeholders in the pharmaceutical industry, particularly those involved in the treatment of gastrointestinal cancers. The successful enrollment of patients in the Serenta trial could enhance Biodexa's position in the market, potentially influencing competitors focused on similar therapeutic areas.

What's Next

The filing indicates that the next steps include a pre-specified futility analysis and database lock, expected to occur early next year and around the end of next year, respectively. These milestones will be critical in determining the future direction of the eRapa development program.